


About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Seven Areas



Dermatology



Nephrology



Gastroenterology



Neurology



Rheumatology



Ophthalmology



Hematology/Oncology

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications

MARKET DYNAMIX

A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.

REALTIME DYNAMIX

A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.

LAUNCH DYNAMIX

Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.

PATIENT CHART DYNAMIX

A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmask real patient management patterns and uncovers the "why" behind treatment decisions.

PATIENT VOICE DYNAMIX

An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.

PAYER DYNAMIX

Empowers pharmaceutical companies with forward-looking insights from key payer decision makers - enabling market access, brand, and strategy teams to confidently navigate evolving coverage and reimbursement landscapes, while preparing for potential policy-driven disruptions.

SPECIAL TOPIX

Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.

For a complete index of available reports, visit
www.clientportal.spherixglobalinsights.com



2026 Dermatology Publications

Alopecia Areata

| | |
|----------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Alopecia Areata, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Leqselvi (SUN Pharma) in Alopecia Areata, US |

Atopic Dermatitis

| | |
|-----------------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Atopic Dermatitis, USAtopic Dermatitis, JP |
| REALTIME DYNAMIX | <ul style="list-style-type: none">Atopic Dermatitis, EU5 |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Ebglyss (Eli Lilly) in Atopic Dermatitis, USNemluvio (Galderma) in Atopic Dermatitis, USVtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Atopic Dermatitis, US |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">Atopic Dermatitis, US |

Chronic Spontaneous Urticaria

| | |
|-----------------------|---|
| MARKET DYNAMIX | <ul style="list-style-type: none">Chronic Spontaneous Urticaria, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Dupixent (Sanofi/Regeneron) in CSU, USRhapsido (Novartis) in CSU, US |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Chronic Spontaneous Urticaria, US |

Cross Indications / Specialty

| | |
|---------------|--|
| SPECIAL TOPIX | <ul style="list-style-type: none">Biologic Coordinators Across Dermatology, USPayer Management Strategies, US |
|---------------|--|

Hidradenitis Suppurativa

| | |
|----------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Hidradenitis Suppurativa, USHidradenitis Suppurativa, EU5 |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Bimzelx (UCB) in Hidradenitis Suppurativa, US |

Plaque Psoriasis

| | |
|-----------------------|--|
| REALTIME DYNAMIX | <ul style="list-style-type: none">Plaque Psoriasis, USPlaque Psoriasis, EU5 |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Icotrokinra (J&J) in Plaque Psoriasis, US |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">Plaque Psoriasis, US |
| SPECIAL TOPIX | <ul style="list-style-type: none">The Oral Opportunity in Plaque Psoriasis, US |

Prurigo Nodularis

| | |
|----------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Prurigo Nodularis, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Nemluvio (Galderma) in Prurigo Nodularis, US |

Other Dermatology Indications

| | |
|----------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Asthma, USAsthma, EUChronic Obstructive Pulmonary Disease, USChronic Obstructive Pulmonary Disease, EUVitiligo, US |
|----------------|--|

Key

| | |
|-----------------------|--|
| MARKET DYNAMIX | Yearly market overview of key indication |
| REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| PATIENT VOICE DYNAMIX | Independent service capturing patient journey insights |
| PAYER DYNAMIX | Payer priorities and tactics compared across therapy areas |
| SPECIAL TOPIX | Current events on specific interest areas |



| Eosinophilic Esophagitis | |
|----------------------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Eosinophilic Esophagitis, US |
| Inflammatory Bowel Disease | |
| MARKET DYNAMIX | <ul style="list-style-type: none">Crohn's Disease, JPUlcerative Colitis, JP |
| REALTIME DYNAMIX | <ul style="list-style-type: none">Crohn's Disease, USCrohn's Disease, EU5Ulcerative Colitis, USUlcerative Colitis, EU5 |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Tremfya (Janssen) in Crohn's Disease, USOmvoH (Eli Lilly) in Crohn's Disease, USTremfya (Janssen) in Ulcerative Colitis, US |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Inflammatory Bowel Disease New Starts, USInflammatory Bowel Disease Switching, USInflammatory Bowel Disease Switching, EU5 |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">Inflammatory Bowel Disease, US |
| SPECIAL TOPIX | <ul style="list-style-type: none">Biologic Coordinators in Gastroenterology, USThe Role of APPs in IBD |
| Obesity | |
| MARKET DYNAMIX | <ul style="list-style-type: none">Obesity, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Oral Semaglutide (Novo Nordisk) in Obesity, USOrforglipron (Eli Lilly) in Obesity, USCagriSema (Novo Nordisk) in Obesity, US |

| MASH | |
|------------------------------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">MASH, USMASH, EU5 |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Rezdiffra (Madrigal) in MASH, USWegovy (Novo Nordisk) in MASH, US |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">MASH, US |
| SPECIAL TOPIX | <ul style="list-style-type: none">MASH Screening and Management among PCPs and Endocrinologists, US |
| Other Gastroenterology Indications | |
| MARKET DYNAMIX | <ul style="list-style-type: none">Celiac Disease, US |
| REALTIME DYNAMIX | <ul style="list-style-type: none">Irritable Bowel Syndrome, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Iqirvo (Ipsen) in Primary Biliary Cholangitis, USLinerixibat (GSK) in Cholestatic Pruritus Among PBC Patients, USLivdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US |
| SPECIAL TOPIX | <ul style="list-style-type: none">The Business of Gastroenterology, US |
| Cross Specialty | |
| SPECIAL TOPIX | <ul style="list-style-type: none">Payer Management Strategies, US |

Key

| | |
|-----------------------|--|
| MARKET DYNAMIX | Yearly market overview of key indication |
| REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| PATIENT VOICE DYNAMIX | Independent service capturing patient journey insights |
| PAYER DYNAMIX | Payer priorities and tactics compared across therapy areas |
| SPECIAL TOPIX | Current events on specific interest areas |



| Lupus | |
|-----------------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Cutaneous Lupus, US (2026 refresh)Systemic Lupus Erythematosus, USSystemic Lupus Erythematosus Pipeline Refresh, USSystemic Lupus Erythematosus, EU5Lupus Nephritis, China |
| REALTIME DYNAMIX | <ul style="list-style-type: none">Lupus Nephritis, USLupus Nephritis, EU5Lupus Nephritis, BrazilLupus Nephritis, Canada |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Gazyva (Genentech) in Lupus Nephritis, US |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Lupus Nephritis, USSystemic Lupus Erythematosus , USSystemic Lupus Erythematosus & Lupus Nephritis, EU5Cutaneous Lupus, US |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">Systemic Lupus Erythematosus & Lupus Nephritis, US |

| Spondyloarthritis (AS, nr-AxSpA, and PsA) | |
|---|---|
| MARKET DYNAMIX | <ul style="list-style-type: none">Ankylosing Spondylitis & nr-AxSpA, USAnkylosing Spondylitis & nr-AxSpA, EU5 (2025)Psoriatic Arthritis, EU5 (2025) |
| REALTIME DYNAMIX | <ul style="list-style-type: none">Psoriatic Arthritis, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Bimzelx (UCB) in AS & nr-AxSpA, USBimzelx (UCB) in Psoriatic Arthritis, USSotyktu (BMS) in Psoriatic Arthritis, US* |

| Other Rheumatology Indications | |
|--------------------------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Idiopathic Inflammatory Myopathies, US (2026 Refresh)Rheumatoid Arthritis, US (2026 Refresh)Rheumatoid Arthritis, EU5 (2025)Sjogren's Disease, US (2025)Systemic Sclerosis, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Rinvoq (AbbVie) in Giant Cell Arteritis, USIanalumab (Novartis) in Sjogren's Disease, US* |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">Systemic Sclerosis, US |
| SPECIAL TOPIX | <ul style="list-style-type: none">ILD in Rheumatology, US (2026 Refresh)Cell Therapy in Rheumatology, USBiologic Coordinators Across Rheumatology, US |
| Cross Specialty | |
| SPECIAL TOPIX | <ul style="list-style-type: none">Payer Management Strategies, US |

| | | |
|-----|-----------------------|--|
| Key | MARKET DYNAMIX | Yearly market overview of key indication |
| | REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| | LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| | PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| | PATIENT VOICE DYNAMIX | Independent service capturing patient journey insights |
| | PAYER DYNAMIX | Payer priorities and tactics compared across therapy areas |
| | SPECIAL TOPIX | Current events on specific interest areas |

*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



2026 Nephrology Publications

| Rare Disease | |
|-----------------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">• Membranous Nephropathy, US |
| REALTIME DYNAMIX | <ul style="list-style-type: none">• IgA Nephropathy, US• IgA Nephropathy, EU5 |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">• Fabhalta in C3G• Empaveli in C3G• Fabhalta in IgAN• Vanrafia in IgAN• Sibeprenlimab in IgAN• Filspari in FSGS*• Atacicept in IgAN*• Povetacicept in IgAN* |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">• Focal Segmental Glomerulosclerosis, US• IgA Nephropathy, US• IgA Nephropathy, EU5• IgA Nephropathy, JP• IgA Nephropathy, China |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">• IgA Nephropathy, US |

| CKD, Dialysis & Transplant | |
|----------------------------|---|
| MARKET DYNAMIX | <ul style="list-style-type: none">• Transplant Rejection, US |
| REALTIME DYNAMIX | <ul style="list-style-type: none">• Dialysis–Nephrologists, US• Dialysis, Renal Dietitians/NP/PA, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">• Vafseo (Akebia) in Renal Anemia, US• OLC (Unicycive) in Hyperphosphatemia, US* |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">• Chronic Kidney Disease, Non-Dialysis, Nephrologists, US• Chronic Kidney Disease, Non-Dialysis, PCPs, US• Dialysis, US |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">• Chronic Kidney Disease, US |
| SPECIAL TOPIX | <ul style="list-style-type: none">• Feedback from ASN Kidney Week, US |

| Cross Specialty | |
|-----------------|---|
| SPECIAL TOPIX | <ul style="list-style-type: none">• Payer Management Strategies, US |

Key

| | |
|-----------------------|--|
| MARKET DYNAMIX | Yearly market overview of key indication |
| REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| PATIENT VOICE DYNAMIX | Independent service capturing patient journey insights |
| PAYER DYNAMIX | Payer priorities and tactics compared across therapy areas |
| SPECIAL TOPIX | Current events on specific interest areas |

*Pending approvals and launch



Alzheimer's Disease

MARKET
DYNAMIX

- Alzheimer's Disease, US

PATIENT VOICE
DYNAMIX

- Alzheimer's Disease, US

Migraine

REALTIME
DYNAMIX

- Migraine, 2 Wave, US

Multiple Sclerosis

MARKET
DYNAMIX

- Multiple Sclerosis, US

LAUNCH
DYNAMIX

- Tolebrutinib, (Sanofi) nrSPMS, US

Psychiatric Indications

MARKET
DYNAMIX

- Psychosis in Schizophrenia, US
- Major Depressive Disorder (MDD), US
- Schizophrenia, US

Generalized Myasthenia Gravis

REALTIME
DYNAMIX

- Generalized Myasthenia Gravis, US
- Generalized Myasthenia Gravis, EU5

PATIENT CHART
DYNAMIX

- Generalized Myasthenia Gravis, US
- Generalized Myasthenia Gravis, EU5

PATIENT VOICE
DYNAMIX

- Generalized Myasthenia Gravis, US

LAUNCH
DYNAMIX

- Uplizna, (Amgen) Generalized Myasthenia Gravis (gMG), US
- Imaavy, (J&J) Generalized Myasthenia Gravis (gMG), US
- Gefurulimab, (Alexion/AZ) Generalized Myasthenia Gravis (gMG), US*
- Cemdisiran, (Regeneron) Generalized Myasthenia Gravis (gMG), US*

Other Neurology Indications

MARKET
DYNAMIX

- Chronic Inflammatory Demyelinating Polyneuropathy, US

SPECIAL
TOPIX

- Cell Therapy in Neurology Indications, US

Cross Specialty

SPECIAL
TOPIX

- Payer Management Strategies, US

Key

| | |
|-----------------------|--|
| MARKET DYNAMIX | Yearly market overview of key indication |
| REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| PATIENT VOICE DYNAMIX | Independent service capturing patient journey insights |
| PAYER DYNAMIX | Payer priorities and tactics compared across therapy areas |
| SPECIAL TOPIX | Current events on specific interest areas |



Diabetic Macular Edema & Neovascular Age-Related Macular Degeneration

| | |
|------------------|--|
| REALTIME DYNAMIX | <ul style="list-style-type: none">Diabetic Macular Edema & AMD, US |
|------------------|--|

Cross Specialty

| | |
|---------------|---|
| SPECIAL TOPIX | <ul style="list-style-type: none">Payer Management Strategies, US |
|---------------|---|

Neovascular Age-Related Macular Degeneration

| | |
|-----------------------|--|
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Age-Related Macular Degeneration, US |
|-----------------------|--|

Other Ophthalmology Indications

| | |
|----------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Diabetic Retinopathy, US |
| SPECIAL TOPIX | <ul style="list-style-type: none">Gene Therapies in Retina, US |

Key

| | |
|-----------------------|--|
| MARKET DYNAMIX | Yearly market overview of key indication |
| REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| PATIENT VOICE DYNAMIX | Independent service capturing patient journey insights |
| PAYER DYNAMIX | Payer priorities and tactics compared across therapy areas |
| SPECIAL TOPIX | Current events on specific interest areas |



B-Cell Malignancies

| | |
|-----------------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">B-Cell Malignancies, USLarge B-Cell Lymphoma, EU |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Large B-Cell Lymphoma, EUChronic Lymphocytic Leukemia, US |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">B-Cell Malignancies, US |

Bleeding Disorders

| | |
|-----------------------|---|
| MARKET DYNAMIX | <ul style="list-style-type: none">Hemophilia A & B, USHemophilia A & B, EU5Von Willebrand Disease, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Qfitlia in Hemophilia A & BHypmavzi in Hemophilia A & BAlhemo in Hemophilia A & B |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">People with Bleeding Disorders |
| SPECIAL TOPIX | <ul style="list-style-type: none">Women, Girls, and people who have or have had the potential to menstruate (WGPPM) with Bleeding Disorders |

Hemoglobinopathies

| | |
|-----------------------|---|
| MARKET DYNAMIX | <ul style="list-style-type: none">Sickle Cell Disease, USThalassemia, US |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Mitapivat in Thalassemia* |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Sickle Cell Disease, USThalassemia, US |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">Sickle Cell Disease, US |

Cross Specialty

| | |
|---------------|---|
| SPECIAL TOPIX | <ul style="list-style-type: none">Payer Management Strategies, US |
|---------------|---|

Solid Tumors

| | |
|------------------|---|
| REALTIME DYNAMIX | <ul style="list-style-type: none">PD-1 Inhibition in Solid Tumors, US |
|------------------|---|

Multiple Myeloma

| | |
|-----------------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Multiple Myeloma, EU5 |
| REALTIME DYNAMIX | <ul style="list-style-type: none">Multiple Myeloma, US |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Multiple Myeloma, US |
| PATIENT VOICE DYNAMIX | <ul style="list-style-type: none">Multiple Myeloma, US |
| SPECIAL TOPIX | <ul style="list-style-type: none">Smoldering Myeloma, US |

Acute Myeloid Leukemia

| | |
|-----------------------|--|
| REALTIME DYNAMIX | <ul style="list-style-type: none">Acute Myeloid Leukemia, US |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Acute Myeloid Leukemia, US |

Myeloproliferative Neoplasms (MPN)

| | |
|----------------|--|
| MARKET DYNAMIX | <ul style="list-style-type: none">Myeloproliferative Neoplasms, US |
|----------------|--|

Paroxysmal Nocturnal Hemoglobinuria

| | |
|-----------------------|---|
| MARKET DYNAMIX | <ul style="list-style-type: none">Paroxysmal Nocturnal Hemoglobinuria, US |
| PATIENT CHART DYNAMIX | <ul style="list-style-type: none">Paroxysmal Nocturnal Hemoglobinuria, US |

Other Benign Hematology Indications

| | |
|----------------|---|
| MARKET DYNAMIX | <ul style="list-style-type: none">Warm Autoimmune Hemolytic Anemia (w-AIHA)Immune Thrombocytopenic Purpura (ITP) |
| LAUNCH DYNAMIX | <ul style="list-style-type: none">Nipocalimab in w-AIHA*Wayrilz in ITP |

Key

| | |
|-----------------------|--|
| MARKET DYNAMIX | Yearly market overview of key indication |
| REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| PATIENT VOICE DYNAMIX | Independent service capturing patient journey insights |
| PAYER DYNAMIX | Payer priorities and tactics compared across therapy areas |
| SPECIAL TOPIX | Current events on specific interest areas |

*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



**Looking for more?
Visit the Spherix Portal**

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

**Create your free account at
www.clientportal.spherixglobalinsights.com**